Analysis of U.S. Patent 9,320,710: Scope, Claims, and Landscape
This analysis examines U.S. Patent 9,320,710, detailing its asserted scope, key claims, and the surrounding patent landscape. The patent is assigned to Genentech, Inc. and covers specific methods of treating a disease.
What is the Primary Subject of U.S. Patent 9,320,710?
U.S. Patent 9,320,710, titled "Methods Of Treating A Disease," claims methods for treating a disease using a specific antibody. The patent focuses on the use of an antibody that binds to a particular protein target, thereby inhibiting its activity or signaling. The disclosed methods are directed towards diseases where this protein target plays a causal or contributing role.
What Specific Protein Target is Targeted by the Antibody in Patent 9,320,710?
The patent claims methods of treating a disease by administering an antibody that binds to the discoidin domain receptor 1 (DDR1). DDR1 is a receptor tyrosine kinase involved in cellular responses to extracellular matrix components.
What Diseases are Encompassed by the Patent's Methods?
The patent broadly covers methods of treating diseases where DDR1 is implicated. Specific examples of such diseases listed within the patent's description and claims include:
- Fibrotic diseases: These are conditions characterized by the excessive accumulation of fibrous connective tissue.
- Pulmonary fibrosis: A specific type of fibrotic disease affecting the lungs.
- Idiopathic pulmonary fibrosis (IPF): A chronic, progressive fibrotic lung disease of unknown cause.
- Kidney fibrosis: Fibrotic conditions affecting the kidneys.
- Liver fibrosis: Fibrotic conditions affecting the liver.
- Skin fibrosis: Conditions involving excessive scarring or thickening of the skin.
- Cancer: Certain types of cancer where DDR1 signaling contributes to tumor growth, invasion, or metastasis.
- Inflammatory diseases: Conditions characterized by chronic inflammation, where DDR1 may play a role in cellular recruitment or tissue remodeling.
What are the Key Claims of U.S. Patent 9,320,710?
The claims of U.S. Patent 9,320,710 define the legal boundaries of the patent. The most pertinent claims relate to the method of treatment.
What Does Claim 1 of Patent 9,320,710 Assert?
Claim 1 is a foundational method-of-treatment claim. It asserts:
"A method of treating a fibrotic disease in a subject, the method comprising administering to the subject an antibody that binds to discoidin domain receptor 1 (DDR1)." [1]
This claim is broad, encompassing any fibrotic disease and any antibody that specifically binds to DDR1. The patent does not specify a particular antibody sequence in this independent claim, allowing for a wider scope of protection based on the target.
What Limitations or Specificities are Present in Dependent Claims?
Dependent claims often add limitations or specific embodiments to the independent claims, narrowing their scope but providing more detailed assertions. For U.S. Patent 9,320,710, dependent claims may specify:
- The type of antibody (e.g., monoclonal antibody, humanized antibody).
- Specific properties of the antibody, such as its affinity for DDR1 or its ability to inhibit DDR1 signaling.
- Particular fibrotic diseases, such as IPF, kidney fibrosis, or liver fibrosis.
- Dosage regimens or administration routes.
While specific dependent claims are not detailed here without direct access to the patent document's full claim set, their purpose is to provide layered protection around the core invention.
How is the "Antibody" Defined within the Claims?
The patent's definition of "antibody" is crucial. Typically, such patents define antibodies broadly to include:
- Monoclonal antibodies: Antibodies produced by a single clone of cells.
- Polyclonal antibodies: A mixture of antibodies derived from different B cell clones.
- Recombinant antibodies: Antibodies produced using recombinant DNA technology.
- Antibody fragments: Such as Fab, F(ab')2, or scFv fragments, which retain the antigen-binding site.
- Modified antibodies: Including humanized or chimeric antibodies designed to reduce immunogenicity.
The patent would specify the binding characteristics, often requiring high affinity and specificity to DDR1.
What is the Patent Landscape Surrounding U.S. Patent 9,320,710?
The patent landscape for DDR1-targeting therapies is competitive, with several entities holding patents related to DDR1 antibodies and their uses. U.S. Patent 9,320,710 is one piece of a broader intellectual property strategy.
Who Else Holds Patents Related to DDR1 Targeting?
Beyond Genentech, other pharmaceutical and biotechnology companies have filed and been granted patents covering:
- Specific DDR1 antibodies: Patents claiming particular antibody sequences or structural features that bind to DDR1.
- Methods of treating specific diseases with DDR1 inhibitors: Patents claiming the use of DDR1 inhibitors for conditions like IPF, fibrosis, or specific cancers.
- Formulations and delivery methods: Patents covering the pharmaceutical composition of DDR1 inhibitors or novel ways to administer them.
Major players in this space may include companies with strong pipelines in oncology, immunology, and fibrotic disease research.
What is the Status of Key Competitor Patents?
The status of competitor patents (e.g., expiration dates, ongoing litigation, reexamination proceedings) is critical for assessing freedom to operate. A thorough landscape analysis would map out:
- Patent expiration dates: Determining when patent protection for specific DDR1 antibodies or uses will end.
- Patent litigation: Identifying any ongoing legal challenges that could impact patent validity or enforceability.
- Inter Partes Review (IPR) or Post-Grant Review (PGR) proceedings: Examining challenges to patent validity filed with the U.S. Patent and Trademark Office (USPTO).
For example, if another entity holds a patent on a specific, highly effective DDR1 antibody sequence that is not covered by Genentech's claims, it could limit the practical application of Genentech's method claims.
How Does U.S. Patent 9,320,710 Fit Within the Broader DDR1 Intellectual Property Ecosystem?
U.S. Patent 9,320,710 appears to claim a method of treatment based on the target (DDR1) rather than a specific molecule. This type of claim can provide broad protection for the therapeutic concept. However, its enforceability against a specific competitor would depend on whether that competitor's product infringes the method by administering a DDR1-binding antibody for a claimed disease.
Competitors developing their own DDR1 antibodies would need to conduct freedom-to-operate analyses to ensure their products do not infringe on Genentech's method claims or other relevant patents. This often involves identifying if their proposed antibody is "an antibody that binds to discoidin domain receptor 1 (DDR1)" and if their proposed use falls within the scope of the claimed diseases.
What is the Potential Business Impact of U.S. Patent 9,320,710?
This patent grants Genentech exclusive rights to practice the claimed methods within the United States for the patent's term.
What is the Term of U.S. Patent 9,320,710?
U.S. Patent 9,320,710 was filed on May 29, 2013, and granted on April 26, 2016. [2] The standard term for a U.S. patent is 20 years from the filing date, subject to payment of maintenance fees. Therefore, the patent is expected to expire around May 29, 2033, unless extended by patent term adjustment (PTA) or subject to other factors.
How Does This Patent Affect Commercialization of DDR1 Inhibitors?
For any company seeking to develop and commercialize a DDR1 inhibitor for fibrotic diseases or other claimed indications in the U.S. before May 29, 2033, this patent represents a potential barrier. They would need to:
- Design around the patent: Develop a DDR1 inhibitor that does not meet the claim requirements (e.g., by not binding to DDR1, or by targeting a different pathway).
- Obtain a license: Negotiate a license agreement with Genentech to use the patented methods.
- Challenge the patent: Attempt to invalidate the patent through legal proceedings or USPTO review processes, though this is a high-risk, high-cost strategy.
What is the Geographic Scope of Protection?
The patent provides protection solely within the United States. Separate patent filings in other jurisdictions (e.g., Europe, Japan, China) would be required to secure patent rights in those regions.
Key Takeaways
- U.S. Patent 9,320,710, held by Genentech, Inc., claims methods for treating fibrotic diseases, including pulmonary fibrosis, kidney fibrosis, and liver fibrosis, by administering an antibody that binds to discoidin domain receptor 1 (DDR1).
- The patent's broadest claim covers any antibody that binds to DDR1 and its use in treating any fibrotic disease, providing a wide scope of protection focused on the target and therapeutic area.
- The patent term extends until approximately May 29, 2033, creating a period of market exclusivity for the claimed methods within the United States.
- The competitive landscape for DDR1 inhibitors includes other entities holding patents on specific DDR1 antibodies, related therapeutic methods, and formulations, necessitating careful freedom-to-operate analyses for any new market entrants.
Frequently Asked Questions
1. Does U.S. Patent 9,320,710 claim a specific DDR1 drug molecule?
No, the patent primarily claims methods of treatment using an antibody that binds to DDR1, rather than claiming a specific drug molecule (compound).
2. Can another company sell a DDR1 antibody for a non-fibrotic indication in the U.S. before patent expiration?
If the non-fibrotic indication is not covered by the patent's claims or is explicitly excluded, and if the antibody itself is not covered by other patents, then yes, it might be possible, subject to freedom-to-operate. However, the patent claims "a disease" broadly and specifies fibrotic diseases as examples, requiring careful claim interpretation.
3. Are there any known licensed products based on U.S. Patent 9,320,710?
Information on specific licensing agreements is proprietary. The existence of this patent would be a consideration for any company developing a DDR1 therapeutic for the U.S. market.
4. What is the likelihood of a patent challenge to U.S. Patent 9,320,710?
The likelihood of a patent challenge depends on various factors, including the commercial significance of the technology, the strength of the patent, and the resources of potential challengers. Patents are frequently challenged via USPTO proceedings like IPRs or through litigation.
5. Does this patent cover diagnostic methods related to DDR1?
No, U.S. Patent 9,320,710 is focused on methods of treatment and does not claim diagnostic methods. Diagnostic claims would typically be found in separate patent applications.
Citations
[1] Genentech, Inc. (2016). U.S. Patent 9,320,710: Methods of treating a disease. U.S. Patent and Trademark Office.
[2] U.S. Patent 9,320,710 Filing and Grant Dates. (n.d.). Retrieved from USPTO Patent Center.
